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Abstract
The current study evaluated amyloid-b oligomers (Abo) in cerebrospinal fluid as a clinical biomarker for Alzheimer’s disease
(AD). We developed a highly sensitive Abo ELISA using the same N-terminal monoclonal antibody (82E1) for capture and
detection. CSF samples from patients with AD, mild cognitive impairment (MCI), and healthy controls were examined. The
assay was specific for oligomerized Ab with a lower limit of quantification of 200 fg/ml, and the assay signal showed a tight
correlation with synthetic Abo levels. Three clinical materials of well characterized AD patients (n = 199) and cognitively
healthy controls (n = 148) from different clinical centers were included, together with a clinical material of patients with MCI
(n = 165). Abo levels were elevated in the all three AD-control comparisons although with a large overlap and a separation
from controls that was far from complete. Patients with MCI who later converted to AD had increased Abo levels on a group
level but several samples had undetectable levels. These results indicate that presence of high or measurable Abo levels in
CSF is clearly associated with AD, but the overlap is too large for the test to have any diagnostic potential on its own.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
affecting more than 15 million people in the world and is
characterized by progressive neuronal degeneration with deposi-
tions of amyloid plaques and neurofibrillary tangles [1]. The
amyloid plaques have been shown to mainly consist of aggregated
amyloid-b (Ab) 1–42, while the neurofibrillary tangles consist of
aggregated phosphorylated tau [2,3]. The pathological process is
believed to begin 10–20 years before the first clinical symptoms
arise, with amyloid plaque formation starting in the neocortex and
can later on be seen throughout the brain [4]. As an intermediate
state before Ab forms plaques, small soluble aggregates called Ab
oligomers (Abo) are believed to be formed [5,6,7]. Animal studies
in rodents have shown that small soluble Abo impair memory [8],
affect long term potentiation [9], and lead to cognitive deficits
[10]. The neurotoxic effects of Abo appear to involve modulation
of the NMDA receptor and metabotropic glutamate receptors and
possibly also pore formation in membranes [11,12,13,14]. The
neurotoxic effect can be reversed in rodents by using immuno-
therapy against Ab and by inhibiting Ab oligomerization with
peptides [15,16,17,18].
Today, three established cerebrospinal fluid (CSF) biomarkers
are used to aid the diagnosis of AD; increased phosphorylated tau
(P-tau181), increased total tau (T-tau), and decreased Ab1–42, for
review see [19]. Several studies have demonstrated that Ab1–42
levels are decreased in AD patients compared to healthy controls,
and this is also reported in patients with prodromal AD [20,21,22].
Amyloid plaques in the brain can be visualized by positron
emission tomography (PET), using the ligand 11C-PIB, which
binds to fibrillar Ab [23]. The belief is that the lowering of Ab1–42
is caused by its incorporation into plaques, which is consistent with
studies showing that high 11C-PIB binding correlates with lower
levels of Ab1–42 in CSF [24,25]. If this lowering is caused by Ab
oligomerization and aggregation, Abo would potentially be an
early biomarker for AD reflecting an ongoing pathology.
In CSF, Abo has been measured with various techniques
[26,27,28,29]. Fukumoto and co-workers recently showed high
CSF levels of Abo in AD patients using and assay based on the
monoclonal antibody BAN50 both for capture and detection and
synthetic Abo as standard [30]. Using flow cytometry, Santos and
co-workers [31] showed that there was a trend of elevated Abo
levels in AD patients compared to controls and Gao and co-
workers [32] also found increased levels of oligomeric Ab1–40 in
CSF using a novel misfolded protein assay. Using nanoparticle
detection an increase in amyloid-b-derived diffusible ligands has
also been reported [29].
In this study, we developed a sandwich ELISA using the same
N-terminally specific Ab antibody as both capture and detection
antibody to measure Abo in CSF. N-terminally specific antibodies
have been demonstrated to have higher affinity against fibrillar Ab
than antibodies with an epitope against the more C-terminal part
of the Ab sequence [33,34], indicating that the N-terminal part of
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the Ab sequence is the most likely one to be exposed in Ab
aggregates. We compared four patient materials with AD patients
to healthy controls, and also a longitudinal mild cognitive
impairment (MCI) cohort, to evaluate whether Abo measured
with this type of assay could be used as a clinical biomarker.
Materials and Methods
Participants
Four study populations were recruited at three specialized and
coordinated memory clinics in Sweden within the Swedish Brain
Power network (Malmo¨, Stockholm and Pitea˚). The Pitea˚ and
Stockholm centers are run by the same clinician with identical
sampling and storage protocols and are hence considered as one
center. Demographics and biochemical characteristics are given in
Table 1. A set of nine younger controls from the Malmo¨ clinic,
median age 42, were included to study possible age effects. All
subjects underwent an extensive clinical examination, also
including cognitive evaluations with mini-mental state examina-
tion (MMSE) [35]. All patients also underwent imaging of the
brain and lumbar puncture for CSF collection.
Controls had no history or clinical signs of neurological or
psychiatric disease or cognitive symptoms. AD was diagnosed
following the criteria for probable AD according to the National
Institute of Neurological and Communicative Disorders and
Stroke- Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) [36]. Disease severity was evaluated using
MMSE scores and mild patients had a MMSE of 25–30; moderate
AD patients had a MMSE of 17–24, and severe AD patients had a
MMSE of 16 or lower. MCI was diagnosed in patients with
cognitive impairment that did not fulfill the criteria for dementia
[37]. During clinical follow-up of the patients with MCI at
baseline, 35% developed AD and 30% developed other forms
dementia disorders, but 47% were cognitively stable for a median
time of 6.3 years (range 3.0y to 9.6y).
CSF collection was conducted following standardized operating
procedures [19]. Lumbar puncture was performed in the L3–L4
or L4–L5 interspace. The first 12 mL of CSF was collected in a
polypropylene tube and was centrifuged at 20006g at 4uC for
10 min. The supernatant was pipetted off, gently mixed to avoid
possible gradient effects, and aliquoted in polypropylene tubes that
were stored at 280uC pending biochemical analyses.
Ethics Statement
The studies were approved by the ethics committees at Lund
University, Umea˚ University and Karolinska Institute. The
participants provided their verbal informed consent for research,
documented in the patient journals, which is the standard
procedure in Sweden and approved by the ethics committees.
Amyloid-b Oligomer ELISA
For the Abo ELISA the Ab N-terminal specific antibody 82E1
[38] (IBL international, Hamburg, Germany) was used both for
capture and detection. The use of the same monoclonal antibody
for capture and detection has been demonstrated in previous
studies to specifically detect aggregated forms of Ab without
detecting monomers [30,39,40,41]. A synthetic dimer consisting of
two Ab1–11 peptides with an added C-terminal cysteine through
which the peptides were coupled via a disulfide bridge (Caslo,
Denmark) was used to create the standard curve. A schematic
outline of the Abo ELISA is presented in Figure 1A.
An ELISA plate (Black MaxiSorp FluoroNunc, Nunc, Den-
mark) was coated with 82E1 diluted in 50 mM NaHCO3, pH 9.6
to a concentration of 1 mg/ml, 100 ml/well, over night in +4uC.
The plate was washed 5 times with 350 ml phosphate buffered
saline containing 0.05% Tween20 (Bio-Rad) (PBST). Blocking was
done using 2% bovine serum albumin (BSA) (Sigma Aldrich)
dissolved in PBST, 300 ml/well at room temperature (RT) for 1 h.
The plate was then washed 5 times with PBST. The standard was
prepared by dilution of the synthetic dimer in 0.1% BSA-PBST,
200–102,000 fg/ml. CSF samples and standards were added in
duplicates, 100 ml/well and incubated for 1 h at RT, where after
the plate was washed 5 times with PBST. Detection antibody,
biotinylated 82E1, diluted in 0.1% BSA-PBST to a concentration
of 750 ng/ml, was added, 100 ml/well, and incubated for 1 h in
RT. The plate was washed 5 times with PBST. NeutrAvidin
horseradish peroxidase conjugate (Thermo Scientific), diluted
Table 1. Demographics and biomarker concentrations for all AD patients, MCI patients and controls.
Study Diagnosis Nr Sex (M/F) Age (years) Ab1–42 (pg/ml)
P-tau181
(pg/ml) T-tau (pg/ml) MMSE Abo (fg/ml)
I Control 31 16/15 61 (52, 67) 690 (466, 898) 47 (33, 61) 285 (188, 365) 29 (28, 29) 522 (339, 781)
AD 42 10/32 79 (74, 81)*** 370 (318, 415)*** 92 (80, 116)*** 770 (640, 895)*** 21 (19, 23)*** 1040 (773, 1,303)***
II Control 22 10/12 69 (66, 72) 780 (645, 1,060) – 405 (178, 500) 30 (30, 30) 0 (0, 0)
AD 51 22/29 79 (75, 81)*** 440 (326, 508)*** – 623 (465, 858)*** 23 (20, 26)*** 717 (0, 1,490)***
III Control 62 17/45 74(68, 78) 298 (237, 342) 33 (23, 41) 79 (56, 97) 29 (28, 30) 0 (0, 0)
MCI-AD 58 21/37 78(73, 81) 146 (119, 177)*** 49 (36, 67)*** 129 (93, 181)** 26 (25, 27)*** 0 (0, 313)**
MCI-Stable 77 34/43 67(62, 75)*** 266(217, 298)** 27(19, 36)* 71 (50, 90) 28 (28, 29)** 0 (0, 295)
IV Control 33 13/20 69 (62, 72) 867 (737, 1060) – 383 (250, 502) 30 (30, 30) 1538 (504, 2408)
Severe 11 7/4 79 (68, 82)** 398 (366, 400)*** – 937 (648, 1270)*** 12 (13, 16)*** 1250 (576, 2082)
Moderate 51 21/30 80 (75, 83)*** 435 (370, 494)*** – 760 (595, 886)*** 21 (20, 23)*** 2647 (1395, 3451)***
Mild 44 18/26 77 (74, 81)*** 473 (440, 524)*** – 848 (631, 899)*** 27 (26, 28)*** 2467 (1250, 3387)**
Data are given as medians with 25th and 75th percentiles.
*p,0.05,
**p,0.01,
***p,0.001 vs. control group.
The analyses of Ab1–42, P-tau181 and T-tau have been performed with ELISA earlier [22,48,49,50].
doi:10.1371/journal.pone.0066381.t001
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1:5,000 in 0.1% BSA-PBST, was added, 100 ml/well, and
incubated for 1 h at RT, and the plate was washed 5 times with
PBST. For detection SuperSignal Femto maximum sensitivity
substrate (Thermo Scientific, Pierce Biotechnology, Rockford,
Illinois, USA) 100 ml/well was used, read 1 s/well on a Victor X4
(Perkin Elmer). The read-out data from Victor X4 were analyzed
with SoftMax Pro 4.7.1 (Molecular Devices).
The detection was done using a colorimetric method for the
oligomerization study and on the analyses of brain tissue. TMB
substrate (Bio-Rad), 100 ml/well was incubated at RT for 15 min,
and the reaction was stopped with 100 ml of 2 M H2SO4.
Absorbance was measured at 450 nm using a V-Max microplate
reader (Molecular Devices).
All samples for each individual study were analyzed on the same
day.
ThT Oligomerization Assay
To initiate the oligomerization, a buffer solution containing
ThT (Sigma-Aldrich) was added to synthetic Ab1–42 (Anaspec),
reconstituted in 10 mM NaOH. The final concentrations were
200 mM HEPES, pH 8, 40 mM ThT, and 40 mM Ab1–42. The
mixture was transferred to a black 384-well microtiter plate (Nunc,
Denmark) and overlaid with mineral oil (Sigma-Aldrich) to
prevent evaporation. Fluorescence was measured at 37uC in
kinetic mode every 30 min using a SpectraMax Gemini XPS
(Molecular Devices) with excitation and emission wavelengths of
450 nm and 485 nm, respectively. One vial with the exact same
reagents was in parallel kept in 37uC from which samples were
taken at given time points, quickly frozen, and stored at 280uC
pending the Abo ELISA analysis.
Cross Reactivity
To test the cross reactivity to monomeric Ab in the Abo ELISA,
Ab1–16 was diluted in 0.1% BSA-PBST in concentrations up to
100,000 pg/ml, while Ab1–40 was diluted up to 5,000 pg/ml and
measured with the Abo ELISA.
Brain Tissue from AD Patients and Tg2576 Mice
Cortical tissue from Tg2576 mice were prepared as described
previously [42]. In brief the brain cortices were homogenized in a
Tris buffer and centrifuged at 16.0006g where after the
supernatants were collected and analyzed. Human AD brain
was homogenized in Tris buffer containing Complete Proteasin-
hibitor (Roche, Protease Inhibitor Cocktail tablets) and 0.5%
Triton x-100, and centrifuged at 30,0006g for 60 min at 4uC. The
supernatant was analyzed.
Freeze/thawing Experiments
CSF samples (n = 4) were thawed and kept in room temperature
and then re-frozen at 280uC in 5 cycles. An identical sample was
kept in 280uC that did not undergo the freeze/thaw cycles to be
used as control.
Heterophilic Antibodies
A set of eight CSF samples, with Abo concentration range of
600–4800 fg/mL, were used to evaluate whether heterophilic
antibodies interfere with the assay. The CSF samples were mixed
with mouse IgG (Sigma-Aldrich, I5381) to a concentration of
10 mg/mL and incubated for 30 minutes before being analyzed
together with the same samples without added mouse IgG.
Molecular Weight Filtration of Oligomers
Synthetic Abo generated according to Berghorn et al [43] were
sequentially spun through different sized molecular weight cut-off
filters (Amicon ultra, Millipore), 50 kDa, 30 kDa, and 10 kDa and
the fractions from these were analyzed.
Statistics
Statistical analyses were performed with SPSS PASW 18 (SPSS
Inc, Chicago, Illinois, USA), using nonparametric tests because of
skewed distribution in the variables. For comparisons between
groups Mann Whitney U-test was used, and data are presented as
median with interquartile range. Correlation analyses were done
using the Spearman correlation coefficient. Scatter plots were
done using GraphPad Prism v5.02 (GraphPad Software Inc, La
Jolla, California, USA).
Results
Abo ELISA Characteristics
The standard curve used in the Abo assay ranged from 200 fg/
mL to 102,400 fg/mL, Figure 1B. The limit of quantification was
determined to 200 fg/mL by calculating the Abo concentration at
10 standard deviations above the blank.
The specificity for the assay was tested using oligomerized Ab1–
42, generated according to the protocol developed by Berghorn
et al [43], which followed a titration curve. In contrast, spiking
with monomeric Ab1–16 up to 100,000 pg/ml or monomeric Ab1–
40 up to 5,000 pg/ml did not result in any detectable concentra-
tion. The specificity for oligomerized Ab was also seen when a
ThT assay was performed in parallel to the Abo ELISA. As can be
seen in Figure 1C there is no reaction at time point zero, with a
dramatic increase between 2–24 hours. The Abo ELISA also
showed an earlier detection of Abo formation than the ThT assay
(Figure 1C). The assay was also tested for interference from
heterophilic antibodies by mixing CSF with mouse IgG, allowing
potential heterophilic antibodies to react with the mouse IgG and
thus block their ability to cross-react with the capture and
detection antibody. This showed no significant decrease in the
Abo signal.
With the Abo assay, it was possible to measure Abo in brain
extracts from transgenic mice. The concentrations of soluble Abo
in brain cortex tissue from Tg2576 mice extracted with TBS were
106 pg Abo/mg protein at the age of 7 days and decreased to
67 pg Abo/mg protein at the age of 90 days. In human AD brain
an Abo concentration of 826 pg/mg protein was measured. The
assay reacts with synthetic oligomers with a molecular weight
Figure 1. ELISA method for Ab oligomers in cerebrospinal fluid. A) Schematic drawing of the principle for the method. Left: The Abo ELISA is
based on the use of the same N-terminal anti-Ab monoclonal antibody twice. The ELISA plate is coated with 82E1 to capture all forms of Ab, while
biotinylated 82E1 is used for detection. A synthetic Ab dimer, with two N-termini, is used as standard. Middle: Abos, with several free N-terminals, are
detected in the assay. Right: monomeric Ab will have their epitopes blocked by the capture antibody and are thus not detected by the detection
antibody. B) Example of a typical standard curve from the Abo assay. The standard curve ranges from 200–102,400 fg/mL. The assay has a lower limit
of quantification of 200 fg/mL. C) Measurement of synthetic Abo formation by the Abo ELISA. Synthetic Ab1–42 was allowed to aggregate into Ab
oligomers. The signal in the Abo ELISA was compared with a Thioflavin-T (ThT) assay for aggregated Ab. The Abo ELISA detects the formation of
synthetic Abo at an earlier stage than the ThT assay, while following the increase of oligomerization in parallel with the ThT assay after 5 hours.
doi:10.1371/journal.pone.0066381.g001
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above 10 kDa, showing reactivity for Abo with a molecular weight
of 10–30 kDa, 30–50 kDa, and .50 kDa.
The measured values of the freeze/thawed samples did not
significantly diverge from samples that did not undergo these
cycles. The coefficient of variation (CV) of the freeze/thawed
sample compared to the control samples where in the range 1–
18%. The intra-assay CV was less than 7% determined by
measuring 7 CSF samples in duplicate. The inter-assay CV was
less than 20%.
Clinical Studies on the Diagnostic Performance of CSF Ab
Oligomers
In the first clinical study, we found a significant (p,0.0001)
increase in AD CSF Abo compared to the control group
(Figure 2a), 1040 fg/mL and 522 fg/mL respectively. However,
there was a marked overlap between the two groups, 64% of AD
patients had a CSF level of Abo higher than the optimal cut-off of
835 fg/mL (84% specificity).
For this reason, we analyzed a second clinical study of AD
patients with dementia from another clinical center. We could
verify a significant (p,0.001) increase in the CSF levels of Abo
compared to the control group (Figure 2b), 717 fg/mL and
,200 fg/mL respectively. However, again there was a marked
overlap between the two groups, 67% of AD patients had CSF
levels of Abo higher than the optimal cut-off of 215 fg/mL (86%
specificity).
We then hypothesized that there may be a more marked release
of Abo into CSF during the earlier stages of the disease. We
therefore analyzed an independent clinical study including patients
with MCI. In this clinical study (Figure 2C), we found that MCI
patients who later converted to AD (MCI-AD) had increased levels
of Abo compared to controls, p,0.01, ,200 fg/mL and 210 fg/
mL respectively, while patients with stable MCI did not differ from
controls, ,200 fg/ml and ,200 fg/mL respectively. However,
there was a marked overlap between MCI-AD and controls, with
only 44% of MCI-AD patients having CSF Abo levels above the
cut-off of 230 fg/mL (85% specificity).
Last, we tested the reverse hypothesis, that there may be a more
marked release of Abo into CSF during the very last stages of the
disease. The basis for this hypothesis was that plaques may act as a
reservoir for aggregated Ab, which in the later stages of the disease
might have reached their maximal capacity, causing Abo to leak
Figure 2. Cerebrospinal fluid Ab oligomers in independent clinical samples. A) First AD study (Malmo¨). Increased CSF levels of Abo in the
AD group (n = 42) compared to the control group (n = 31), p,0.0001. Bars indicate median with interquartile range. B) Second AD study (Pitea˚ and
Stockholm). Increased CSF levels of Abo in the group of patients with AD (n = 51) compared to the control group (n = 22), p,0.001. Bars indicate
median with interquartile range. C) MCI study. Increased CSF levels of Abo in the group of MCI patients who converted to AD during the follow-up
period (n = 58) as compared to the control group (n = 62), p,0.01. No significant difference in CSF Abo between stable MCI (p = 0.059) and controls.
Bars indicate median with interquartile range. D) Clinical study on AD with different severity of dementia. Increased CSF levels of Abo in the group of
AD patients with mild (n = 44, p,0.01) and moderate (n = 51, p,0.001) dementia as compared to the control group (n = 33). No significant change
was found in the AD group with severe dementia (n = 11) compared to the control group. Bars indicate median with interquartile range.
doi:10.1371/journal.pone.0066381.g002
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out from the brain into the CSF. We therefore analyzed an
independent clinical study with AD patients with different severity
of dementia (mild – moderate – severe) based on their MMSE
scores. In this clinical study (Figure 2D) we found that AD patients
with mild (2467 fg/mL) and moderate (2647 fg/mL) dementia
had significantly higher levels of Abo compared to healthy controls
(1538 fg/mL), p,0.01 and p,0.001 respectively, while AD
patients with severe dementia (1250 fg/mL) did not significantly
differ from the control group (Figure 2d).
Abo in Relation to Established Biomarkers for AD
In all four studies, the levels of the three established biomarkers
were significantly changed in the AD vs. control population, with
decreased Ab1–42, increased P-tau181, and increased T-tau in the
AD group (Table 1). This was also seen in the MCI patients who
later converted to AD (Table 1).
No significant correlations were found between Abo and the
biomarkers in any of the control, AD or MCI groups.
Influence of Age on Abo
The age of the subjects did not correlate with Abo levels in any
of the groups. A comparison between younger healthy controls
against the healthy controls in study I, both sampled at the same
clinic, did not show any significant age difference between the Abo
levels, 1160 fg/mL vs. 580 fg/mL respectively, p = 0.277.
Discussion
In this study we evaluated if CSF Abo could be used as a clinical
biomarker for AD by analyzing four different patient materials
from different clinical centers. Three patient materials were
analyzed, where AD patients consistently had significantly
increased levels of Abo compared to controls. In one study stable
MCI and MCI-AD patients were analyzed, which showed an
increase in Abo in MCI-AD patients but not in stable MCI
patients.
We developed a highly sensitive and specific CSF Abo ELISA,
similar to the one used by Xia et al [44], where we used a synthetic
Ab dimer with two free N-terminals, instead of a preparation of
aggregated Ab1–42 used in earlier studies [30,32] to create the
standard curve and a chemiluminescent substrate for detection.
The use of a synthetic dimer enables quantification and
comparisons of results longitudinally since the dimer is stable
and at known concentrations. This gives an Abo concentration
which is relative to the dimer, and the signal from a synthetic
oligomer mixture correlates with the dimer concentration when
titrated in parallel, why differences in Abo levels between AD and
controls won’t be affected by the use of a dimer instead of a
mixture of synthetic oligomers. The Abo ELISA was run in
parallel with a ThT assay showing that the oligomerization of
Ab1–42 measured by the Abo ELISA followed the results from the
ThT assay. The assay detects Abo larger than 10 kDa which
includes slightly smaller Abo than Fukumoto et al [30] detect with
their assay, but the clinical relevance of these are unknown. No
correlation was found between age and Abo levels in the patient
groups, and there was no significant difference in Abo levels
between younger and older healthy controls. A relatively high
amount of Abo was detected in human brain tissue from AD
patients confirming that it could also detect naturally occurring
Abo. Abo was also detected in the brains from transgenic Tg2576
mice, overexpressing human Ab, where the Abo levels decreased
with age, which is the opposite to findings on the same mice with a
different type of Abo assay [42]. This might reflect that the two
assays detect different populations of Abo, where the assay used in
this paper seems to detect oligomers that are present at highest
concentration early in the disease. A potential risk with these kinds
of assays is the presence of heterophilic antibodies which could
cause a false positive signal, although mainly affecting plasma
samples [45]. To show that the Abo signals was not caused by
heterophilic antibodies, a set of CSF samples were spiked with a
high concentration of irrelevant mouse IgG, to quench potential
heterophilic antibodies, and then measured with the Abo ELISA.
This did not show a decrease in the Abo levels indicating that the
signals were not caused by heterophilic antibodies.
Patients with AD would be expected to have increased
concentrations of Abo since this would reflect the AD pathogenesis
with aggregation of Ab in the brain leading to amyloid plaques.
Although it has been reported that the amyloid plaque burden in
the brain weakly correlates with the severity of dementia in AD
patients [46]. We found higher levels of CSF Abo in AD patients,
although we could not find any correlation between Ab1–42 and
Abo in any of the studies. This would indicate that the lowering of
CSF Ab1–42 is not, at least solely, explained by its incorporation
into oligomeric forms. The same has been suggested for plasma Ab
and Abo [44]. Only a small fraction of Ab1–40 and Ab1–42, which
are in the high pg/mL to low ng/mL range, seems to be in
oligomeric form in CSF, perhaps because the oligomers are stuck
in the brain.
We detected that patients with MCI who later converted to AD
had increased levels of Abo compared to controls, while this
increase in Abo was not seen in patients with stable MCI.
Although this difference was seen on a group level, many of the
samples had lower Abo levels than could be measured using our
Abo ELISA. The overlap of the Abo values between the MCI-AD
group and control group was substantial and should thus be
interpreted with caution. When comparing AD patients that were
divided according to their MMSE scores to study how oligomers
varied at different stages of AD, we found that AD patients with
mild and moderate AD had significantly higher levels of Abo than
controls, while AD patients with severe AD did not differ
significantly from the control group. It almost seems as if Abo
levels increase at the onset of the disease when the clinical
symptoms appear, and then rises as the disease progresses to later
fall back down as the disease gets severe.
To our knowledge no previous study has measured CSF Abo on
several patient materials spanning different stages of AD. In some
of the patient materials many of the samples had undetectable or
very low levels of Abo. We cannot explain why the number of
patients who had undetectable levels of Abo varied among the
different studies, although there could be some differences in the
materials used for sampling CSF at the different centers. There
were also some controls in our study who had relatively high levels
of Abo for unknown reason. The controls have been followed up
to ensure that they did not develop AD in the near future,
minimizing the risk of them having incipient AD although it
cannot be fully excluded given that the disease has an onset many
years before clinical symptoms [21,22]. The differences in the
patients materials are not likely due to freeze/thawing since we
could not detect any loss or gain in Abo levels when CSF samples
were freeze/thawed in five cycles. It has been shown that Ab is not
affected by long term storage [47], although it cannot be
completely ruled out that storage conditions might affect the
levels of oligomeric forms of the protein. The samples for each
study were sampled at one clinical centre and stored in the same
way, minimizing possible artifacts from long term storage or
differences in sample handling. Even though various techniques
have been used to measure CSF Abo [26,27,28,29,30,31,32], and
what was seen in our study, the results seem to remain the same
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with an increase of Abo in AD and MCI-AD patients, although
with a marked overlap to the controls, resulting in a too weak
separation to be considered as a clinical biomarker at this stage.
However, as a marker in clinical studies, Abo can be monitored
within patients to measure if CSF Abo are reduced as an effect of
these treatments. This would indicate that the compounds reach
their target and reduce the levels of the neurotoxic Abo.
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